These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 21533858)

  • 41. [Expression of hypoxia inducible factor-1alpha and glucose transporter protein 1 in renal and bladder cancers and the clinical significance thereof].
    Zhou JT; Cai ZM; Li NC; Na YQ
    Zhonghua Yi Xue Za Zhi; 2006 Jul; 86(28):1970-4. PubMed ID: 17064593
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Expression of cell cycle-associated proteins in non-muscle-invasive bladder cancer: correlation with intravesical recurrence following transurethral resection.
    Behnsawy HM; Miyake H; Abdalla MA; Sayed MA; Ahmed Ael-F; Fujisawa M
    Urol Oncol; 2011; 29(5):495-501. PubMed ID: 19914103
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prognostic factors for primary superficial transitional cell carcinoma of the bladder: a retrospective cohort study.
    Yang TB; Zeng FH; Sun ZQ
    Chin Med J (Engl); 2006 Nov; 119(21):1821-8. PubMed ID: 17097038
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Analysis of the relationship between expression of caveolin-1 and prognosis in bladder transitional cell carcinoma].
    Ruan J; Weng ZL
    Zhonghua Zhong Liu Za Zhi; 2010 Jun; 32(6):429-31. PubMed ID: 20819483
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Wnt5a / planar cell polarity signaling pathway in urothelial carcinoma, a potential prognostic biomarker.
    Saling M; Duckett JK; Ackers I; Coschigano K; Jenkinson S; Malgor R
    Oncotarget; 2017 May; 8(19):31655-31665. PubMed ID: 28427201
    [TBL] [Abstract][Full Text] [Related]  

  • 46. CD147 overexpression is a prognostic factor and a potential therapeutic target in bladder cancer.
    Xue YJ; Lu Q; Sun ZX
    Med Oncol; 2011 Dec; 28(4):1363-72. PubMed ID: 20509007
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Expression of p53 and mdm2 and their significance in recurrence of superficial bladder cancer.
    Tuna B; Yörükoğlu K; Tüzel E; Güray M; Mungan U; Kirkali Z
    Pathol Res Pract; 2003; 199(5):323-8. PubMed ID: 12908522
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Expression of ras p21 oncogene product on human bladder tumors.
    Moriyama N; Umeda T; Akaza H; Taniguchi J; Kitamura T; Murakami T; Kawabe K; Aso Y
    Urol Int; 1989; 44(5):260-3. PubMed ID: 2678672
    [TBL] [Abstract][Full Text] [Related]  

  • 49. ErbB2, ErbB3 and ErbB4 expression in urothelial tumors of the upper urinary tract and their prognostic significance.
    Galanakis I; Spyropoulos E; Gkialas I; Nomikos A; Souka E; Mitropoulos D
    J BUON; 2013; 18(3):653-9. PubMed ID: 24065479
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Decreased DOC-2/DAB2 expression in urothelial carcinoma of the bladder.
    Karam JA; Shariat SF; Huang HY; Pong RC; Ashfaq R; Shapiro E; Lotan Y; Sagalowsky AI; Wu XR; Hsieh JT
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4400-6. PubMed ID: 17671122
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Primary High-Grade Non-Muscle-Invasive Bladder Cancer: High NFκB Expression in Tumor Specimens Distinguishes Patients Who are at Risk for Disease Progression.
    Mitrakas L; Gravas S; Papandreou C; Koukoulis G; Karasavvidou F; Dimakopoulos G; Weingärtner K; Karatzas A; Zachos I; Tzortzis V
    Pathol Oncol Res; 2019 Jan; 25(1):225-231. PubMed ID: 29081034
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The prognostic importance of e-cadherin and p53 gene expression in transitional bladder carcinoma patients.
    Serdar A; Turhan C; Soner G; Cem SN; Bayram K; Damla BE; Erbil E
    Int Urol Nephrol; 2005; 37(3):485-92. PubMed ID: 16307325
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Slingshot homolog-1 expression is a poor prognostic factor of pT1 bladder urothelial carcinoma after transurethral resection.
    Luo Q; Liu Y; Zhao H; Guo P; Wang Q; Li W; Li G; Wu B
    World J Urol; 2020 Nov; 38(11):2849-2856. PubMed ID: 31965287
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Loss expression of uroplakin III is associated with clinicopathologic features of aggressive bladder cancer.
    Matsumoto K; Satoh T; Irie A; Ishii J; Kuwao S; Iwamura M; Baba S
    Urology; 2008 Aug; 72(2):444-9. PubMed ID: 18313120
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immunohistochemical expression of metallothionein in human bladder cancer: correlation with histopathological parameters and patient survival.
    Saga Y; Hashimoto H; Yachiku S; Tokumitsu M; Kaneko S
    J Urol; 2002 Nov; 168(5):2227-31. PubMed ID: 12394764
    [TBL] [Abstract][Full Text] [Related]  

  • 56. DNA-malignancy-grading of bladder tumor and its clinical significance.
    Wang XZ; Ma YJ; Zheng JF; Qin HY
    Chin Med J (Engl); 1992 Oct; 105(10):856-9. PubMed ID: 1291205
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cell Cycle Markers in the Evaluation of Bladder Cancer.
    da Silva JNL; Ranzi AD; Carvalho CT; Scheide TV; Strey YTM; Graziottin TM; Bica CG
    Pathol Oncol Res; 2020 Jan; 26(1):175-181. PubMed ID: 29524168
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prognostic role of the tumor-associated tissue inflammatory reaction in transitional bladder cell carcinoma.
    Cai T; Nesi G; Boddi V; Mazzoli S; Dal Canto M; Bartoletti R
    Oncol Rep; 2006 Aug; 16(2):329-34. PubMed ID: 16820911
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prognostic significance of p53 protein accumulation in stage pT1 transitional cell carcinoma of the bladder.
    Toktaş G; Türkeri LN; Unlüer E; Atuğ F; Murat C; Ozveren B; Calişkan M; Akdaş A
    Int Urol Nephrol; 1999; 31(4):437-41. PubMed ID: 10668937
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prostate stem cell antigen predicts tumour recurrence in superficial transitional cell carcinoma of the urinary bladder.
    Elsamman E; Fukumori T; Kasai T; Nakatsuji H; Nishitani MA; Toida K; Ali N; Kanayama HO
    BJU Int; 2006 Jun; 97(6):1202-7. PubMed ID: 16686711
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.